Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2444996 | 1.00 | HSD11B1 (0.58) | HSD11B1HSD11B2 | |
| Hydrochloric Acid SCHEMBL16495263 | 0.99 | HSD11B1 (0.57) | HSD11B1HSD11B2 | |
| Hydrochloric Acid SCHEMBL16495262 | 0.99 | HSD11B1 (0.57) | HSD11B1HSD11B2 | |
| SCHEMBL14680490 | 0.87 | HSD11B1 (0.55) | HSD11B1HSD11B2 | |
| SCHEMBL1847058 | 0.87 | HSD11B1 (0.56) | HSD11B1HSD11B2 | |
| SCHEMBL1847057 | 0.87 | HSD11B1 (0.56) | HSD11B1HSD11B2 | |
| SCHEMBL12578947 | 0.87 | HSD11B1 (0.56) | HSD11B1HSD11B2 | |
| SCHEMBL974114 | 0.87 | HSD11B1 (0.56) | HSD11B1HSD11B2 | |
| SCHEMBL974113 | 0.87 | HSD11B1 (0.56) | HSD11B1HSD11B2 | |
| SCHEMBL974112 | 0.87 | HSD11B1 (0.56) | HSD11B1HSD11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8530477-B2 | Tropane urea derivatives, preparation thereof and therapeutic application thereof as modulators of the activity of 11betaHSD1 | SANOFI (FR) | 2013-09-10 | — | — | US | disclosed |
| EP-2364311-B1 | TROPANE UREA DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF AS MODULATORS OF THE ACTIVITY OF 11BETAHSD1 | SANOFI SA (FR) | 2013-07-03 | — | — | EP | disclosed |
| US-20110294809-A1 | TROPANE UREA DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF AS MODULATORS OF THE ACTIVITY OF 11BETAHSD1 | SANOFI-AVENTIS (FR) | 2011-12-01 | — | — | US | disclosed |
| EP-2364311-A1 | TROPANE UREA DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF AS MODULATORS OF THE ACTIVITY OF 11BETAHSD1 | SANOFI (FR) | 2011-09-14 | — | — | EP | disclosed |
| WO-2010049635-A1 | TROPANE UREA DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF AS MODULATORS OF THE ACTIVITY OF 11BETAHSD1 | SANOFI-AVENTIS (FR) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294809-A1 | TROPANE UREA DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF AS MODULATORS OF THE ACTIVITY OF 11BETAHSD1 | HSD11B1, HSD17B1, HSD17B11 | HSD11B1 1/4885HSD11B2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.